CytomX Therapeutics, Inc.
CTMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 2.02 | -0.06 | -0.03 |
| FCF Yield | -99.50% | -49.71% | -106.98% | -43.43% |
| EV / EBITDA | 2.18 | -25.81 | 0.71 | -0.83 |
| Quality | ||||
| ROIC | 62.20% | 2.20% | -90.18% | -43.76% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -2.71 | 98.48 | 1.12 | 1.42 |
| Growth | ||||
| Revenue 3-Year CAGR | 37.47% | 39.46% | -8.07% | -13.42% |
| Free Cash Flow Growth | -52.16% | 49.46% | 6.72% | -4,189.49% |
| Safety | ||||
| Net Debt / EBITDA | -1.07 | 0.74 | 1.78 | 1.62 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 8.20 | 12.38 | 247.07 | 7.73 |